

1. Robert, C., and Kupper, T.S. 1999. Inflammatory skin diseases, T cells, and immune surveillance. *N. Engl. J. Med.* **341**:1817–1828.
2. Schon, M.P., Zollner, T.M., and Boehncke, W.H. 2003. The molecular basis of lymphocyte recruitment to the skin – clues for the pathogenesis and selective therapies for inflammatory disorders. *J. Invest. Dermatol.* In press.
3. Kansas, G.S. 1996. Selectins and their ligands: current concepts and controversies. *Blood.* **88**:3259–3287.
4. Labow, M.A., et al. 1994. Characterization of E-selectin-deficient mice: demonstration of overlapping function of the endothelial selectins. *Cell.* **1**:709–720.
5. Bhushan, M., et al. 2002. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. *Br. J. Dermatol.* **146**:824–831.
6. Thoma, G., Banteli, R., Jahnke, W., Magnani, J.L., and Patton, J.T. 2001. A readily available, highly potent E-selectin antagonist. *Angew. Chem. Int. Ed. Engl.* **40**:3644–3647.
7. Schon, M.P., et al. 2002. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. *Nat. Med.* **8**:366–372.
8. Dimitroff, C.J., Bernacki, R.J., and Sackstein, R. 2003. Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. *Blood.* **101**:602–610.
9. Schottelius, A.J., Hamann, A., and Asadullah, K. 2003. Role of fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity. *Trends Immunol.* **24**:101–104.
10. Maly, P., et al. 1996. The alpha(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. *Cell.* **86**:643–653.
11. Smithson, G., et al. 2001. Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. *J. Exp. Med.* **194**:601–614.
12. Compain, P., and Martin, O.R. 2001. Carbohydrate mimetics-based glycosyltransferase inhibitors. *Bioorg. Med. Chem.* **9**:3077–3092.
13. Lee, L.V., et al. 2003. A potent and highly selective inhibitor of human alpha-1,3-fucosyltransferase via click chemistry. *J. Am. Chem. Soc.* **125**:9588–9589.
14. Bengtson, P., Lundblad, A., Larson, G., and Pahlsson, P. 2002. Polymorphonuclear leukocytes from individuals carrying the G329A mutation in the alpha 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins. *J. Immunol.* **169**:3940–3946.
15. Dimitroff, C.J., Kupper, T.S., and Sackstein, R. 2003. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. *J. Clin. Invest.* **112**:1008–1018. doi:10.1172/JCI200319220.
16. Asano, M., et al. 1997. Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells. *EMBO J.* **16**:1850–1857.

Finding NEMO: genetic disorders of NF- κ B activation

Jordan S. Orange and Raif S. Geha

Division of Immunology, Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA

The pathways between a receptor and transcriptional activation mediated by NF- κ B are complex. The study of human gene mutations that result in dysregulation of these pathways has provided insight into the functions of individual components of the pathway, their interrelations, and the significance of these systems to the organism (see the related article beginning on page 1108).

J. Clin. Invest. **112**:983–985 (2003). doi:10.1172/JCI200319960.

Inducible activation of gene transcription

NF- κ B was recognized as a DNA-binding factor that exists in the cytoplasm of resting cells and that accumulates in the nucleus under appropriate conditions (1). The ability of NF- κ B to shuttle between the cytoplasm and nucleus in a tightly regulated manner

led to the exploration of a complex series of events leading to activation-induced gene expression, and to the discovery of factors that prevent the transit of NF- κ B into the nucleus (2). Receptor-mediated NF- κ B activation of gene transcription and its stringent control are fundamental to cell development, survival, and function. In this issue of the *JCI*, Courtois and colleagues report a novel human mutation in a protein that negatively regulates NF- κ B activation (3). The resultant mutant dominantly inhibits the activation of NF- κ B (see below) and gives rise to a clinical syndrome of ectodermal dysplasia (ED) and susceptibility to infection.

NF- κ B activity is imparted by a protein dimer selected from five mammalian homologues: p50, p52, p65 (RelA), Rel, and RelB (p50 and p52 are

derived from larger precursors, p105 and p100, respectively). The majority of dimers formed by these individual NF- κ B members are capable of activating transcription by binding to κ B sites in DNA. The dimerization of these molecules occurs through a conserved N-terminal Rel homology domain (RHD). Importantly, the RHD also serves as the binding site for one of several inhibitors of NF- κ B (I κ Bs). An I κ B can physically interfere with NF- κ B dimerization or block nuclear localization sequences within the NF- κ B member. The family of molecules possessing these activities consists of at least seven members: I κ B α , I κ B β , I κ B ϵ , I κ B γ , Bcl-3, and inhibitory domains of the p105 and p100 precursor proteins. The cytoplasmic association of an I κ B and a NF- κ B member is controlled by the phosphorylation of the I κ B, which leads to its ubiquitination and proteosomal degradation (Figure 1). The release of an NF- κ B protein from I κ B allows it to participate in dimer formation, translocate to the nucleus, and activate transcription. The phosphorylation of I κ B, therefore, is a critical regulatory step in NF- κ B function.

NF- κ B activation

Phosphorylation of I κ B is mediated by an I κ B kinase (IKK), a large, multisubunit signaling complex (signalosome) capable of binding I κ B as well as other upstream regulators. The classical IKK signalosome consists of two catalytic subunits, IKK α and IKK β , and a regu-

Address correspondence to: Raif S. Geha, Division of Immunology, Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Phone: (617) 355-7603; Fax: (617) 730-0528; E-mail: Raif.Geha@TCH.harvard.edu.

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: ectodermal dysplasia (ED); inhibitor of NF- κ B (I κ B); I κ B kinase (IKK); NF- κ B essential modulator (NEMO); TNF superfamily receptor (TNFSR); ectodysplasin-A (EDA); EDA receptor (EDAR); Toll-like receptor-4 (TLR-4).




Figure 1 Receptor-induced NF- κ B nuclear translocation and inhibition by a dominant negative I κ B. A variety of cell surface receptors are capable of inducing associated specific signaling complexes that can activate the IKK signalosome to phosphorylate I κ B. This phosphorylation of I κ B leads to its proteosomal degradation, thus liberating NF- κ B dimers and allowing them to regulate gene transcription in the nucleus. The particular signaling complex activated and utilized by a given cell surface receptor varies and is specific to the receptor family. When a mutant I κ B is present, the IKK signalosome is unable to phosphorylate the key serine residues, and NF- κ B is retained in the cytoplasm bound to the mutant protein despite appropriate upstream activation. The octagons represent NF- κ B family members, and individual dimers are frequently heterogeneous. NKR, NK cell activation receptor; TCR, T cell receptor; BCR, B cell receptor.

latory subunit, IKK γ , also known as the NF- κ B essential modulator (NEMO) (4). IKK α is capable of functioning independently of the aforementioned IKK signalosome and has the particular capacity to induce processing of p100 to yield p52 (5). When appropriately activated by phosphorylation, IKK serves as a conduit to the nuclear translocation of NF- κ B and is the bottleneck common to many activation pathways (Figure 1).

Genetic disorders resulting from mutations in the NF- κ B activation pathway

Unique insight into the role of NF- κ B receptor-mediated function has been gained through the study of congenital diseases that affect NF- κ B (Table 1). Investigation of diseases that affect development of the ectoderm have provided evidence for an essential role for NF- κ B in this process. ED is characterized by fine, sparse hair, conical

teeth, and hypohidrosis and has been linked to gene mutations that interfere with the appropriate ligation of the TNF superfamily receptor (TNFSR) ectodysplasin-A receptor (EDAR) or with appropriate EDAR signaling. Mutations can affect the EDAR receptor itself (6), its ligand ectodysplasin-A (EDA) (7, 8), or its associated adaptor protein (EDAR-associated death domain) (9). These mutations result in an inability to activate NF- κ B

Table 1 Genetic disorders of NF- κ B activation in humans

Protein	Gene	Inheritance	Mutation	Pathway affected	ED	Immunodeficiency
EDA	<i>ED1</i>	XR	Amorphic	TNFSR	+	-
EDAR	<i>EDAR</i>	AR	Amorphic	TNFSR	+	-
EDAR-associated death domain	<i>EDARADD</i>	AR	Amorphic	TNFSR	+	-
Cylindromatosis tumor suppressor	<i>CYLD</i>	AD	Loss of suppressor	TNFSR	+/- ^B	-
IL-1 receptor-associated kinase-4	<i>IRAK4</i>	AR	Amorphic	TLR	-	+
NEMO	<i>IKKβ</i>	XR	Hypomorphic	Common	+ ^C	-
		XD ^A	Amorphic	Common	+ ^D	+
I κ B α	<i>IKBA</i>	AD	Gain of function	Common	+	+

^AMale inheritance of amorphic mutation results in embryonic lethality, while female inheritance leads to incontinentia pigmenti (19). ^BResults in uncontrolled outgrowth from eccrine tissues. ^CThe vast majority of patients have ED, but certain hypomorphic mutations can present with immunodeficiency but without ED (J.S. Orange and R.S. Geha, unpublished observations). ^DFemale inheritance of a single amorphic mutation results in incontinentia pigmenti, and male inheritance is embryonic lethal. XR, X-linked recessive; AD, autosomal dominant; AR, autosomal recessive; XD, X-linked dominant.

through the EDAR system during developmental stages critical to ectodermal maturation, resulting in ED. Although these genetic lesions are not associated with immunodeficiency, a subset of patients with ED have variable, but often profound, immunodeficiency. The majority of individuals with ED and immunodeficiency have a hypomorphic X-linked recessive mutation in the gene encoding the NEMO protein (10–13). In addition to impaired EDAR signaling, cells from these boys fail to demonstrate significant nuclear translocation of NF- κ B after exposure to TNF or the Toll-like receptor-4 (TLR-4) ligand LPS. As a result, these individuals have a remarkable susceptibility to disease caused by pyogenic bacteria and mycobacteria.

In this issue of the *JCI*, Courtois and colleagues describe a child with a point mutation in one allele of $\text{I}\kappa\text{B}\alpha$ that results in the inability of the mutant $\text{I}\kappa\text{B}\alpha$ to be phosphorylated (3) (Figure 1). Substitution (S32I) of one of two key serine residues (S32 and S36) that are targets for IKK phosphorylation and are critical for phospho- $\text{I}\kappa\text{B}\alpha$ ubiquitination and degradation results in a dominant gain-of-function inhibitor of NF- κ B. Like boys with a NEMO mutation, the patient had ED as well as combined immunodeficiency characterized by an inability to respond to ligands for TLR and TNFSR, impairment of antibody production and T cell proliferation, and susceptibility to both Gram-positive and Gram-negative bacteria. Unlike many patients with the NEMO mutation (13), he had normal NK cell activity and did not have mycobacterial infection.

Links to upstream receptors

Much of the diversity attributed to NF- κ B functions can be ascribed to specific cell surface receptors that recognize a variety of unrelated ligands. The pathways that link these diverse ligands and families of recep-

tors to activation of IKK are complex. Key receptor families that can activate NF- κ B and induce gene transcription include TLRs, TNFSRs, T and B cell receptors, and NK cell activation receptors. Each of these different groups of receptors activates IKK by utilizing a specific cascade of signaling molecules (with some degree of overlap) that forms a receptor-specific signaling complex. These multifaceted complexes present numerous opportunities for specific activation and regulation. Gene mutations that affect NEMO or $\text{I}\kappa\text{B}\alpha$ will presumably affect all receptors that converge upon IKK. Mutations of proteins functioning in the complex between specific receptors and IKK, however, have also been described (Table 1). They include the cylindromatosis tumor suppressor (CLYD), which negatively regulates TNFSR signaling (14–17), and the IL-1 receptor-associated kinase-4 (IRAK-4), which participates in activation mediated by TLRs (18). Restricted phenotypes resulting from these different mutations, e.g., cutaneous tumors in CLYD mutation and susceptibility to infection in IRAK-4 deficiency, illustrate the function of the mutant proteins and their upstream receptors.

Lessons learned

The discovery of NF- κ B activation disorders is providing great insight into the complex events involved in receptor-mediated NF- κ B-dependent transcriptional activation. Clinical presentations that include ectodermal abnormalities and/or immunodeficiency should prompt evaluation of NF- κ B function and may lead to the appreciation of novel mutations in members of the IKK signalosome and related proteins that affect the function of specific receptors that utilize NF- κ B. These discoveries could provide novel targets for therapeutic intervention in diseases characterized by dysregulated NF- κ B activation.

- Baeuerle, P.A., and Baltimore, D. 1988. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. *Cell*. **53**:211–217.
- Ghosh, S., and Karin, M. 2002. Missing pieces in the NF-kappaB puzzle. *Cell*. **109**(Suppl.):S81–S96.
- Courtois, G., et al. 2003. A hypermorphic $\text{I}\kappa\text{B}\alpha$ mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. *J. Clin. Invest.* **112**:1108–1115. doi:10.1172/JCI200318714.
- Israel, A. 2000. The IKK complex: an integrator of all signals that activate NF-kappaB? *Trends Cell Biol.* **10**:129–133.
- Dejardin, E., et al. 2002. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. *Immunity*. **17**:525–535.
- Monreal, A.W., et al. 1999. Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia. *Nat. Genet.* **22**:366–369.
- Kere, J., et al. 1996. X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. *Nat. Genet.* **13**:409–416.
- Schneider, P., et al. 2001. Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A. *J. Biol. Chem.* **276**:18819–18827.
- Headon, D.J., et al. 2001. Gene defect in ectodermal dysplasia implicates a death domain adapter in development. *Nature*. **414**:913–916.
- Doffinger, R., et al. 2001. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. *Nat. Genet.* **27**:277–285.
- Jain, A., et al. 2001. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia. *Nat. Immunol.* **2**:223–228.
- Zonana, J., et al. 2000. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). *Am. J. Hum. Genet.* **67**:1555–1562.
- Orange, J.S., et al. 2002. Deficient natural killer cell cytotoxicity in patients with IKK- γ /NEMO mutations. *J. Clin. Invest.* **109**:1501–1509. doi:10.1172/JCI200214858.
- Bignell, G.R., et al. 2000. Identification of the familial cylindromatosis tumour-suppressor gene. *Nat. Genet.* **25**:160–165.
- Brummelkamp, T.R., Nijman, S.M., Dirac, A.M., and Bernards, R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. *Nature*. **424**:797–801.
- Trompouki, E., et al. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. *Nature*. **424**:793–796.
- Kovalenko, A., et al. 2003. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. *Nature*. **424**:801–805.
- Picard, C., et al. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. *Science*. **299**:2076–2079.
- Smahi, A., et al. 2000. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. *Nature*. **405**:466–472.